Leveraging Microbial Immunotherapies for Bacterial Vaginosis: Innovations with the DYSCOVER Platform
- Developing microbial immunotherapies for Bacterial Vaginosis (BV) using the DYSCOVER platform to address the imbalance in the vaginal microbiome and reduce inflammation
- Leveraging proof-of-concept studies (DYSCOVER-1 and Dyscover II) to demonstrate the efficacy of Lactobacillus strains in engrafting the vaginal tract and displacing dysbiotic microbiomes
- Mitigating serious consequences in pregnant women by reducing the recurrence of BV and associated risks such as premature rupture of membranes, preterm birth, intra-amniotic infection, low birth weight, and miscarriage